Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Weill Cornell Medical College, New York, NY, USA.
Br J Haematol. 2019 Oct;187(2):157-162. doi: 10.1111/bjh.16151. Epub 2019 Aug 13.
Acute promyelocytic leukaemia differentiation syndrome (APL DS) is seen when patients with APL are treated with all-trans retinoic acid (ATRA) and/or arsenic trioxide (ATO). Presenting symptoms are varied but frequently include dyspnoea, unexplained fever, weight gain >5 kg, unexplained hypotension, acute renal failure and a chest radiograph demonstrating pulmonary infiltrates or pleural or pericardial effusion. Immediate treatment with steroids at the first clinical suspicion is recommended and ATRA/ATO should be stopped in severe cases or if there is no response to treatment. The utility of steroid prophylaxis in order to prevent APL DS is less certain. Here we provide a detailed review of the pathogenesis, clinical signs and symptoms as well as management and prophylaxis strategies of APL DS.
急性早幼粒细胞白血病分化综合征(APL DS)见于接受全反式维甲酸(ATRA)和/或三氧化二砷(ATO)治疗的 APL 患者。其临床表现多样,但常包括呼吸困难、不明原因发热、体重增加>5kg、不明原因低血压、急性肾衰竭和胸片示肺部浸润或胸腔或心包积液。一旦出现临床疑似症状,建议立即使用类固醇进行治疗,在严重情况下或治疗无反应时应停止使用 ATRA/ATO。预防性使用类固醇以预防 APL DS 的疗效尚不确定。本文详细综述了 APL DS 的发病机制、临床体征和症状以及治疗和预防策略。